This type of BIM protein promotes drug resistance in NSCLC (non-small cell lung cancer) and CML (chronic myeloid leukemia) against tyrosine kinase inhibitors such as gefitinib and imatinib[67]. Here, BCL2L11 is linked to non-small cell lung carcinoma.